• Important Safety Information
  • Prescribing Information
  • Support for patients
  • CONDITION Select
    Diabetes Obesity Growth hormone-related disorders Hemophilia and rare bleeding disorders
    • MEDICINE OR PRODUCT Select
    •  
  • Home
  • Saxenda® HCP Support | NovoCare®
  • Start a PA
  • Savings card offer
  • Home
  • Saxenda® HCP Support | NovoCare®
  • Start a PA
  • Savings card offer

Check your patient's insurance coverage and estimated cost

There are two ways for you to get coverage and cost information for your patient. You can complete and fax in the form below to have a NovoCare® representative complete a benefit investigation or you can complete our online form for a response in minutes.

Need assistance now? Call 1-888-809-3942, 8:00am-8:00pm ET, Monday-Friday.

Check your patient's insurance coverage and estimated cost

There are two ways for you to get coverage and cost information for your patient. You can complete and fax in the form below to have a NovoCare® representative complete a benefit investigation or you can complete our online form for a response in minutes.

Need assistance now? Call 1-888-809-3942, 8:00am-8:00pm ET, Monday-Friday.

Online: Complete a short form anytime to find your patient's coverage details and cost in minutes.

Get started

Online: Complete a short form anytime to find your patient's coverage details and cost in minutes.

Get started

Fax: Complete and fax the benefit investigation form to 1-844-667-3475.

Download form

Check your patient's insurance coverage and estimated cost

*Indicates required field

*Indicates required field

Each state decides for itself what prescription drugs to cover through Medicaid, so your patient would need to contact the state Medicaid office to learn if it covers medicines for weight management and obesity.


Unfortunately, Medicare does not cover medicines for obesity. However, some select Medigap and Medicare Advantage plans for retirees do. If your patient has one of these plans, please check with its administrator.


In order to determine coverage, you will need to follow the VA’s “Saxenda® Criteria for Use” guidelines and submit a prior authorization form. Please contact the plan directly for additional assistance.



Next: Patient information

Patient information


Health care provider verification

If this is your first time looking up your patient's cost and coverage, you will be required to complete a one-time registration using your provider information. When using your registered email and NPI you will skip this process.

Look up prescriber NPI number

Prescriber lookup


Look up and verify

Prescriber results

Select the prescriber from the list below.

Next

Provider results

We did not find any health care providers that matched {prescriberFirstName} {prescriberLastName} in {prescriberState}. You can edit your search terms and try again or use the official NPI registry to refine your search.

 

Back

By clicking "Next" I am certifying that I am a licensed practitioner under state law, that the above therapy is medically necessary, and that the information provided is accurate to the best of my knowledge. I further acknowledge that I have obtained the above patient's authorization to release the above information as required by applicable privacy laws, including but not limited to, the Health Insurance Portability and Accountability Act ("HIPAA"), 42 U.S.C. § 1320 et seq., as well as such other information that may be required for Novo Nordisk Inc., and agents working on its behalf, to determine my patient's insurance coverage information.

Next: Finish

We need some more details

Your patient's plan covers this medication, but we can't tell if there are additional plan requirements. In order for us to confirm plan requirements, we will need some more information. Please complete this form and fax it to 844-667-3475. 

Download form

A prior authorization (PA) is required for your patient

NovoCare® integrates CoverMyMeds® support services and online submission capabilities, so you or your office staff can submit PAs right from here.

Get started

A prior authorization (PA) is required for your patient

NovoCare® integrates CoverMyMeds® support services and online submission capabilities, so you or your office staff can submit PAs right from here. If your patient has already met the step therapy requirements, start the PA.

Get started

Provide your patient with a coverage request letter

Since your patient is not covered for Saxenda®, do not start the prior authorization process. Instead, talk to your patient about contacting the benefits manager in his or her Human Resources department. You can provide your patient with a coverage request letter to assist with the process. Download a sample letter that can be used as a guide.

Download

Help your patient save

With the Saxenda® Savings Card, your patient may be eligible to pay as little as ${triplefin.palaAmount} or save up to $200 per {triplefin.daysSupply}-day supply.a

Direct your patient to visit SaxendaSavings.com to activate, request, or print their Saxenda® Savings Card.

aEligibility and other restrictions apply. 

See offer details

Help your patient save

With the Saxenda® Savings Card, your patient's estimated cost is ${triplefin.oopCopayAmount} per {triplefin.daysSupply}-day supply.a

Direct your patient to visit SaxendaSavings.com to activate, request, or print their Saxenda® Savings Card.

aEligibility and other restrictions apply. 

See offer details

A lower cost may be available in the future

It looks like this patient is still in the deductible phase of their plan. Once your patient reaches their prescription drug deductible, they may see a decrease in their co-pay.

Complete this form and we'll investigate

We could not find cost and coverage information for this patient. If you would like us to call the patient's plan for this information, please complete this form and fax it to 844-667-3475. 

Download form

Your patient is covered! Follow up for the cost

Your patient's plan covers this medication, but we will need some more information to determine the cost. Please complete this form and fax it to 844-667-3475. 

Download form

Your patient is covered! Follow up for the cost

Your patient's plan covers this medication, but in order to determine the cost or other restrictions, we will need some more information. Please complete this form and fax it to 844-667-3475. 

Download form

Personalized support with SaxendaCare®

Designed to work along with Saxenda®, SaxendaCare® gives your patient the choice of one-on-one phone coaching with Registered Dietitian Nutritionists or app-based support with Noom. Patients can create reduced-calorie eating and increased activity goals, learn about the Saxenda® pen, and build the skills needed to take each step. All this at no cost.

Direct your patient to SaxendaCare.com

Important Safety Information

Prescribing Information, including Boxed Warning

Visit SaxendaPro.com

Card information

Use the card below as an example to help you find the information you need to complete this request.

Card example

Need help?

Card example

Let us help

If you have questions or would like assistance understanding the results, we are happy to help.

Call: 1-888-809-3942

M-F; 8:00am-8:00pm ET

Card information

Use the card below as an example to help you find the information you need to complete this request.

saxenda-hcp-v7-novocare Skip to main content

Saxenda® Selected Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Saxenda® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Saxenda® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda®.

Indications and Usage

Saxenda® (liraglutide) injection 3 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:

  • Adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)
  • Pediatric patients aged 12 years and older with body weight above 60 kg (132 lbs) and initial BMI corresponding to 30 kg/m2 or greater for adults (obese) by international cut-offs

Limitations of Use

  • Saxenda® contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist.
  • The safety and effectiveness of Saxenda® in pediatric patients with type 2 diabetes have not been established.
  • The safety and effectiveness of Saxenda® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Contraindications

Saxenda® is contraindicated in:

  • Patients with a personal or family history of MTC or patients with MEN 2.
  • Patients with a prior serious hypersensitivity reaction to liraglutide or to any of the excipients in Saxenda®.
  • Pregnancy.

Warnings and Precautions

  • Risk of Thyroid C-cell Tumors: If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide postmarketing. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Saxenda® promptly and if pancreatitis is confirmed, do not restart.
  • Acute Gallbladder Disease: Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in patients treated with Saxenda® than with placebo even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
  • Hypoglycemia: Adult patients with type 2 diabetes on an insulin secretagogue (eg, a sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia with use of Saxenda®. The risk may be lowered by a reduction in the dose of insulin secretagogues or insulin. In pediatric patients without type 2 diabetes, hypoglycemia occurred. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms.
  • Heart Rate Increase: Mean increases in resting heart rate of 2 to 3 beats per minute (bpm) were observed in patients treated with Saxenda®. Monitor heart rate at regular intervals and inform patients to report palpitations or feelings of a racing heartbeat while at rest during treatment with Saxenda®. Discontinue Saxenda® in patients who experience a sustained increase in resting heart rate.
  • Renal Impairment: Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported, usually in association with nausea, vomiting, diarrhea, or dehydration. Use caution when initiating or escalating doses of Saxenda® in patients with renal impairment.
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (eg, anaphylaxis and angioedema) have been reported in patients treated with liraglutide. If a hypersensitivity reaction occurs, patients should stop taking Saxenda® and promptly seek medical advice.
  • Suicidal Behavior and Ideation: In adult clinical trials, 9 (0.3%) of 3,384 patients treated with Saxenda® and 2 (0.1%) of the 1,941 treated with placebo reported suicidal ideation; one of the Saxenda® treated patients attempted suicide. In a pediatric trial, 1(0.8%) of the 125 Saxenda® treated patients died by suicide. There was insufficient information to establish a causal relationship to Saxenda®. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue treatment if patients experience suicidal thoughts or behaviors. Avoid Saxenda® in patients with a history of suicidal attempts or active suicidal ideation.

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% are nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis

Drug Interactions

  • Saxenda® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda®.

Use in Specific Populations

  • There are no data on the presence of liraglutide in human breast milk; liraglutide was present in the milk of lactating rats.
  • Saxenda® has not been studied in patients less than 12 years of age.
  • Saxenda® slows gastric emptying. Saxenda® has not been studied in patients with preexisting gastroparesis.

Please click here for Saxenda® Prescribing Information, including Boxed Warning

Disclaimer   Privacy Policy   Cookie Policy   Contact Us    Novo Nordisk US

Disclaimer   
Privacy Policy   
Cookie Policy   
Contact Us   
Novo Nordisk US

NovoCare® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

© 2021 Novo Nordisk  All rights reserved. US20NC00086  January 2021

You are being redirected to an another page. Do you wish to continue ?

  • Yes
  • No

Loading....